Abstract
Fibroblast growth factor 21 (FGF21) and β-Klotho (KLB) play an important role in preventing and treating overweight and obesity. However, it is unclear what conditions promote FGF21 and KLB expression in different tissues. Therefore, we studied expression of FGF21 and KLB with respect to two exercise regimes: moderate-intensity continuous training (MICT) and high-intensity interval training (HIIT) (two popular strategies in weight loss). Mice were randomly divided into three groups (n = 8 per group): MICT, HIIT, and sedentary lifestyle (SED). All mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity. The exercise was performed on a motorized treadmill for another eight weeks and the diet continued in each group. We found that both MICT and HIIT had positive effects on the loss of HFD-induced body weight increase and serum FGF21 levels. HIIT promoted decrease of the body weight and serum triglyceride (TG) levels, while MICT was more effective at enhancing FGF21 and KLB expression in the liver, brown adipose tissue (BAT), and muscle at the mRNA and protein levels.
Similar content being viewed by others
Abbreviations
- BAT:
-
brown adipose tissue
- eWAT:
-
epididymal white adipose tissue
- FGF21:
-
fibroblast growth factor 21
- FGFR:
-
FGF receptor
- KLB:
-
β-Klotho
- HFD:
-
high-fat diet
- HIIT:
-
high-intensity interval training
- MICT:
-
moderate-intensity continuous training
- SED:
-
sedentary lifestyle
- TG:
-
triglyceride
REFERENCES
Wang, H., Qiang, L., and Farmer, S. R. (2008) Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes, Mol. Cell. Biol., 28, 188-200, doi: https://doi.org/10.1128/Mcb.00992-07.
Lobelo, F., Stoutenberg, M., and Hutber, A. (2014) The exercise is medicine global health initiative: a 2014 update, Br. J. Sports Med., 48, 1627-1668, doi: https://doi.org/10.1136/bjsports-2013-093080.
Nishimura, T., Nakatake, Y., Konishi, M., and Itoh, N. (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver, Biochim. Biophys. Acta, 1492, 203-206, doi: https://doi.org/10.1016/s0167-4781(00)00067-1.
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D. S., Mehrbod, F., Jaskunas, S. R., and Shanafelt, A. B. (2005) FGF-21 as a novel metabolic regulator, J. Clin. Invest., 115, 1627-1635, doi: https://doi.org/10.1172/Jci23606.
Kharitonenkov, A., and Shanafelt, A. B. (2008) Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases, BioDrugs, 22, 37-44, doi: https://doi.org/10.2165/00063030-200822010-00004.
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., and Kharitonenkov, A. (2008) Fibroblast growth factor 21 corrects obesity in mice, Endocrinology, 149, 6018-6027, doi: https://doi.org/10.1210/en.2008-0816.
Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H. F., Weiszmann, J., Lu, S. C., Graham, M., Busby, J., Hecht, R., Li, Y. S., Li, Y., Lindberg, R., and Veniant, M. M. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects, Am. J. Physiol. Endocinol. Metab., 297, 1105-1114, doi: https://doi.org/10.1152/ajpendo.00348.2009.
Fazeli, P. K., Lun, M., Kim, S. M., Bredella, M. A., Wright, S., Zhang, Y., Lee, H., Catana, C., Klibanski, A., Patwari, P., and Steinhauser, M. L. (2015) FGF21 and the late adaptive response to starvation in humans, J. Clin. Invest., 125, 4601-4611, doi: https://doi.org/10.1172/Jci83349.
Wente, W., Efanov, A. M., Brenner, M., Kharitonenkov, A., Koester, A., Sandusky, G. E., Sewing, S., Treinies, I., Zitzer, H., and Gromada, J. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways, Diabetes, 55, 2470-2478, doi: https://doi.org/10.2337/db05-1435.
Bookout, A. L., de Groot, M. H., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., and Kliewer, S. A. (2013) FGF21 regulates metabolism and circadian behavior by acting on the nervous system, Nat. Med., 19, 1147-1152, doi: https://doi.org/10.1038/nm.3249.
Zhang, C., Huang, Z., Gu, J., Yan, X., Lu, X., Zhou, S., Wang, S., Shao, M., Zhang, F., Cheng, P., Feng, W., Tan, Y., and Li, X. (2015) Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway, Diabetologia, 58, 1937-1948, doi: https://doi.org/10.1007/s00125-015-3630-8.
Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F. J., Giralt, M., Mampel, T., and Villarroya, F. (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue, J. Biol. Chem., 286, 12983-12990, doi: https://doi.org/10.1074/jbc.M110.215889.
Fisher, F. M., Adams, A., Antonellis, P., Kharitonenkov, A., Flier, J., and Maratos-Flier, E. (2009) Genetic and diet induced obesity are associated with FGF21 resistance in adipose tissue and liver, Obesity, 17, 68-68.
Mashili, F. L., Austin, R. L., Deshmukh, A. S., Fritz, T., Caidahl, K., Bergdahl, K., Zierath, J. R., Chibalin, A. V., Moller, D. E., Kharitonenkov, A., and Krook, A. (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity, Diabetes Metab. Res. Rev., 27, 286-297, doi: https://doi.org/10.1002/dmrr.1177.
Kharitonenkov, A., Dunbar, J. D., Bina, H. A., Bright, S., Moyers, J. S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S. F., Knierman, M. D., Hale, J. E., Coskun, T., and Shanafelt, A. B. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho, J. Cell. Physiol., 215, 1-7, doi: https://doi.org/10.1002/jcp.21357.
Petryszak, R., Keays, M., Tang, Y. A., Fonseca, N. A., Barrera, E., Burdett, T., Fullgrabe, A., Fuentes, A. M., Jupp, S., Koskinen, S., Mannion, O., Huerta, L., Megy, K., Snow, C., Williams, E., Barzine, M., Hastings, E., Weisser, H., Wright, J., Jaiswal, P., Huber, W., Choudhary, J., Parkinson, H. E., and Brazma, A. (2016) Expression atlas update – an integrated database of gene and protein expression in humans, animals and plants, Nucleic Acids Res., 44, 746-752, doi: https://doi.org/10.1093/nar/gkv1045.
Diaz-Delfin, J., Hondares, E., Iglesias, R., Giralt, M., Caelles, C., and Villarroya, F. (2012) TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway, Endocrinology, 153, 4238-4245, doi: https://doi.org/10.1210/en.2012-1193.
Wisløff, U., Helgerud, J., Kemi, O. J., and Ellingsen, Ø. (2001) Intensity-controlled treadmill running in rats: VO2 max and cardiac hypertrophy, Am. J. Physiol. Heart Circ. Physiol., 280, 1301-1310, doi: https://doi.org/10.1152/ajpheart.2001.280.3.H1301.
Petot, H., Meilland, R., Le Moyec, L., Mille-Hamard, L., and Billat, V. L. (2012) A new incremental test for VO2 max accurate measurement by increasing VO2 max plateau duration, allowing the investigation of its limiting factors, Eur. J. Appl. Physiol., 112, 2267-2276, doi: https://doi.org/10.1007/s00421-011-2196-5.
Ayachi, M., Niel, R., Momken, I., Billat, V. L., and Mille-Hamard, L. (2016) Validation of a ramp running protocol for determination of the true VO2 max in mice, Front. Physiol., 7, 372, doi: https://doi.org/10.3389/fphys.2016.00372.
Geng, L., Liao, B., Jin, L., Huang, Z., Triggle, C. R., Ding, H., Zhang, J., Huang, Y., Lin, Z., and Xu, A. (2019) Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues, Cell Rep., 26, 2738-2752, doi: https://doi.org/10.1016/j.celrep.2019.02.014.
Somm, E., Henry, H., Bruce, S. J., Aeby, S., Rosikiewicz, M., Sykiotis, G. P., Asrih, M., Jornayvaz, F. R., Denechaud, P. D., Albrecht, U., Mohammadi, M., Dwyer, A., Acierno, J. S., Jr., Schoonjans, K., Fajas, L., Greub, G., and Pitteloud, N. (2017) beta-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue, JCI Insight, 2, e91809, doi: https://doi.org/10.1172/jci.insight.91809.
Tezze, C., Romanello, V., and Sandri, M. (2019) FGF21 as modulator of metabolism in health and disease, Front. Physiol., 10, 419, doi: https://doi.org/10.3389/fphys.2019.00419.
Staiger, H., Keuper, M., Berti, L., Hrabe de Angelis, M., and Haring, H. U. (2017) Fibroblast growth factor 21-metabolic role in mice and men, Endocr. Rev., 38, 468-488, doi: https://doi.org/10.1210/er.2017-00016.
Fisher, F. M., and Maratos-Flier, E. (2016) Understanding the physiology of FGF21, Annu. Rev. Physiol., 78, 223-241, doi: https://doi.org/10.1146/annurev-physiol-021115-105339.
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., and Potthoff, M. J. (2014) Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding, Diabetes, 63, 4057-4063, doi: https://doi.org/10.2337/db14-0595.
Kim, K. H., Kim, S. H., Min, Y. K., Yang, H. M., Lee, J. B., and Lee, M. S. (2013) Acute exercise induces FGF21 expression in mice and in healthy humans, PLoS One, 8, e63517, doi: https://doi.org/10.1371/journal.pone.0063517.
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela-Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez-Chantar, M. L., and Maratos-Flier, E. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease, Gastroenterology, 139, 456-463, doi: https://doi.org/10.1053/j.gastro.2010.04.054.
Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Aktas, B., Celikel, C. A., Ozdogan, O., Imeryuz, N., Kalayci, C., and Avsar, E. (2010) Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease, Eur. J. Clin. Invest., 40, 887-892, doi: https://doi.org/10.1111/j.1365-2362.2010.02338.x.
Chavez, A. O., Molina-Carrion, M., Abdul-Ghani, M. A., Folli, F., Defronzo, R. A., and Tripathy, D. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance, Diabetes Care, 32, 1542-1546, doi: https://doi.org/10.2337/dc09-0684.
Ji, F., Liu, Y., Hao, J. G., Wang, L. P., Dai, M. J., Shen, G. F., and Yan, X. B. (2019) KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese, Aging (Albany NY), 11, 7847-7858, doi: https://doi.org/10.18632/aging.102293.
Samms, R. J., Cheng, C. C., Kharitonenkov, A., Gimeno, R. E., and Adams, A. C. (2016) Overexpression of beta-klotho in adipose tissue sensitizes male mice to endogenous FGF21 and provides protection from diet-induced obesity, Endocrinology, 157, 1467-1480, doi: https://doi.org/10.1210/en.2015-1722.
Hansen, J. S., Clemmesen, J. O., Secher, N. H., Hoene, M., Drescher, A., Weigert, C., Pedersen, B. K., and Plomgaard, P. (2015) Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans, Mol. Metab., 4, 551-560, doi: https://doi.org/10.1016/j.molmet.2015.06.001.
Hansen, J. S., Pedersen, B. K., Xu, G., Lehmann, R., Weigert, C., and Plomgaard, P. (2016) Exercise-induced secretion of FGF21 and Follistatin are blocked by pancreatic clamp and impaired in type 2 diabetes, J. Clin. Endocrinol. Metab., 101, 2816-2825, doi: https://doi.org/10.1210/jc.2016-1681.
Taniguchi, H., Tanisawa, K., Sun, X., Kubo, T., and Higuchi, M. (2016) Endurance exercise reduces hepatic fat content and serum fibroblast growth factor 21 levels in elderly men, J. Clin. Endocrinol. Metab., 101, 191-198, doi: https://doi.org/10.1210/jc.2015-3308.
Yang, S. J., Hong, H. C., Choi, H. Y., Yoo, H. J., Cho, G. J., Hwang, T. G., Baik, S. H., Choi, D. S., Kim, S. M., and Choi, K. M. (2011) Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women, Clin. Endocrinol. (Oxf), 75, 464-469, doi: https://doi.org/10.1111/j.1365-2265.2011.04078.x.
Andersen, T. R., Schmidt, J. F., Thomassen, M., Hornstrup, T., Frandsen, U., Randers, M. B., and Bangsbo, J. (2014) A preliminary study: effects of football training on glucose control, body composition, and performance in men with type 2 diabetes, Scand. J. Med. Sci. Sports, 24, 43-56, doi: https://doi.org/10.1111/sms.12259.
Besse-Patin, A., Montastier, E., Vinel, C., Castan-Laurell, I., Louche, K., Dray, C., and Valet, P. (2014) Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine, Int. J. Obesity, 38, 707-713, doi: https://doi.org/10.1038/ijo.2013.158.
Berglund, E. D., Lustig, D. G., Baheza, R. A., Hasenour, C. M., Lee-Young, R. S., Donahue, E. P., and Wasserman, D. H. (2011) Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver, Diabetes, 60, 2720-2729, doi: https://doi.org/10.2337/db11-0455.
Loyd, C., Magrisso, I. J., Haas, M., Balusu, S., Krishna, R., Itoh, N., and Habegger, K. M. (2016) Fibroblast growth factor 21 is required for beneficial effects of exercise during chronic high-fat feeding, J. Appl. Physiol., 121, 687-698, doi: https://doi.org/10.1152/japplphysiol.00456.2016.
Fletcher, J. A., Linden, M. A., Sheldon, R. D., Meers, G. M., Morris, E. M., Butterfield, A., and Rector, R. S. (2016) Fibroblast growth factor 21 and exercise-induced hepatic mitochondrial adaptations, Am. J. Physiol. Gastrointest. Liver Physiol., 310, 832-843, doi: https://doi.org/10.1152/ajpgi.00355.2015.
Yu, H., Xia, F., Lam, K. S., Wang, Y., Bao, Y., Zhang, J., and Xu, A. (2011) Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans, Clin. Chem., 57, 691-700, doi: https://doi.org/10.1373/clinchem.2010.155184.
Villarroya, F., Cereijo, R., Villarroya, J., and Giralt, M. (2017) Brown adipose tissue as a secretory organ, Nat. Rev. Endocrinol., 13, 26-35, doi: https://doi.org/10.1038/nrendo.2016.136.
Sanchez-Delgado, G., Martinez-Tellez, B., Olza, J., Aguilera, C. M., Gil, A., and Ruiz, J. R. (2015) Role of exercise in the activation of brown adipose tissue, Ann. Nutr. Metab., 67, 21-32, doi: https://doi.org/10.1159/000437173.
Peres Valgas da Silva, C., Hernandez-Saavedra, D., White, J. D., and Stanford, K. I. (2019) Cold and exercise: therapeutic tools to activate brown adipose tissue and combat obesity, Biology (Basel), 8, 9, doi: https://doi.org/10.3390/biology8010009.
BonDurant, L. D., Ameka, M., Naber, M. C., Markan, K. R., Idiga, S. O., Acevedo, M. R., and Potthoff, M. J. (2017) FGF21 regulates metabolism through adipose-dependent and-independent mechanisms, Cell Metab., 25, 935-944, doi: https://doi.org/10.1016/j.cmet.2017.03.005.
Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., and Walsh, K. (2008) FGF21 is an Akt-regulated myokine, FEBS Lett., 582, 3805-3810, doi: https://doi.org/10.1016/j.febslet.2008.10.021.
Izumiya, Y., Hopkins, T., Morris, C., Sato, K., Zeng, L., Viereck, J., Hamilton, J. A., Ouchi, N., LeBrasseur, N. K., and Walsh, K. (2008) Fast/glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice, Cell Metab., 7, 159-172, doi: https://doi.org/10.1016/j.cmet.2007.11.003.
Kim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y. N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., Ko, T., Han, J., Kim, H. L., Kim, J., Back, S. H., Komatsu, M., Chen, H. C., Chan, D. C., Konishi, M., Itoh, N., Choi, C. S., and Lee, M. S. (2013) Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine, Nat. Med., 19, 83-92, doi: https://doi.org/10.1038/nm.3014.
Lindegaard, B., Hvid, T., Grondahl, T., Frosig, C., Gerstoft, J., Hojman, P., and Pedersen, B. K. (2013) Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV, PLoS One, 8, e55632, doi: https://doi.org/10.1371/journal.pone.0055632.
Verzijl, C. R. C., Van De Peppel, I. P., Struik, D., and Jonker, J. W. (2020) Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis, Expert Opin. Investig. Drugs, 29, 125-133, doi: https://doi.org/10.1080/13543784.2020.1708898.
Funding
This research was financially supported by the Ministry of Education of the People’s Republic of China (project no. 20194180050).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare no conflict of interest in financial or any other sphere. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Rights and permissions
About this article
Cite this article
Xiong, Y., Chen, Y., Liu, Y. et al. Moderate-Intensity Continuous Training Improves FGF21 and KLB Expression in Obese Mice. Biochemistry Moscow 85, 938–946 (2020). https://doi.org/10.1134/S000629792008009X
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S000629792008009X